Health
UAE company nears end of Chinese Covid-19 vaccine trial – Devdiscourse
He said G42 has distribution and manufacturing agreements with Sinopharm and hopes to provide the UAE and other regional states with the vaccine, especially tho…
A United Arab Emirates company is nearing the end of Phase III clinical trials of a Chinese COVID-19 vaccine and hopes to manufacture it next year, a representative said. The trial, which began in mid-July, is a partnership between Sinopharm’s China National Biotec Group (CNBG) and Abu Dhabi-based artificial intelligence and cloud computing company Group 42 (G42).
The vaccine uses an inactivated virus; a well-known technology which has been used against diseases such as influenza and measles. T…
-
Noosa News22 hours agoDisaster relief packages announced for flood-stricken western Queensland
-
General16 hours agoLabor to pledge $2.3 billion to subsidise home batteries
-
General22 hours ago307,000 Voices | The Spectator Australia
-
General22 hours agoLive and dead animals seized from Kyneton business after investigation